{
    "symbol": "NEPT",
    "quarter": 3,
    "year": 2023,
    "date": "2023-03-31 18:14:09",
    "content": " Consolidated net sales for the third quarter totaled $12.2 million, down $2.5 million, a 17% decline as compared to the same period last year. Excluding sales from the cannabis business in fiscal Q3 last year, this quarter's net sales increased 8.1% over the prior year due to strength in those core businesses, Sprout and Biodroga. Year-to-date, net sales amounted to $40.5 million, up 8.6% versus prior year and up 19.7% when cannabis sales in both this year and last are excluded. Gross profit for the third quarter of fiscal year '23 amounted to $1.88 million as compared to $1.65 million for the same period last year, while consolidated gross margins improved to 15.1% as compared to 11.3% last year. Net sales for Sprout totaled $8.4 million in Q3, an increase of 18% over the same period last year. Biodroga's Q3 net sales totaled USD 3.6 million, a decrease of 11% as compared to the same period last year. Year-to-date in fiscal '23, however, net sales increased 6% versus the same period last year to $11.8 million. Consolidated SG&A for the quarter amounted to $8.7 million as compared to $18.4 million for the same period the prior year, a reduction of $9.7 million or 52%. Q3 net loss of $497,000, contrast to a net loss of $16.8 million in the same quarter last year, an improvement of $16.6 million for the quarter. Consolidated adjusted EBITDA loss for the third quarter is $4 million as compared to a $14.2 million loss for the same quarter last year, an improvement of $10.2 million. For the year-to-date, the consolidated adjusted EBITDA amounted to a loss of $29 million as compared to a loss of $40.5 million last year, an $11.5 million improvement, much of which occurred in the third quarter."
}